The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats

Shadabul Haque, Colin W. Pouton, Michelle P. McIntosh, David B. Ascher, David W. Keizer, Michael R. Whittaker, Lisa M. Kaminskas

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Polylactide-co-glycolide (PLGA) nanoparticles are one of the most commonly explored biodegradable polymeric drug carriers for inhaled delivery. Despite their advantages as inhalable nanomedicine scaffolds, we still lack a complete understanding of the kinetics and major pathways by which these materials are cleared from the lungs. This information is important to evaluate their safety over prolonged use and enable successful clinical translation. This study aimed to determine how the size and charge of 3H-labeled PLGA nanoparticles affect the kinetics and mechanisms by which they are cleared from the lungs and their safety in the lungs. The results showed that lung clearance kinetics and retention patterns were more significantly defined by particle size, whereas lung clearance pathways were largely influenced by particle charge. Each of the nanoparticles caused transient inflammatory changes in the lungs after a single dose that reflected lung retention times.

Original languageEnglish
Article number102291
Number of pages11
JournalNanomedicine: Nanotechnology, Biology and Medicine
Publication statusPublished - Nov 2020


  • Clearance
  • Lungs
  • Nanoparticles
  • Pharmacokinetics
  • PLGA

Cite this